NVO

81.05

2.95% 2.32

Handel nachbörslich: 81.25 0.20 +0.25%

Novo Nordisk Adr (NVO)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt NVO? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$78.73

Offen:

$80.64

24-Stunden-Volumen:

10.53M

Relative Volume:

1.06

Marktkapitalisierung:

$322.81B

Einnahmen:

$43.59B

Nettoeinkommen (Verlust:

$15.04B

KGV:

24.00

EPS:

3.3766

Netto-Cashflow:

$10.74B

1W Leistung:

+11.56%

1M Leistung:

+19.65%

6M Leistung:

-25.38%

1J Leistung:

-43.42%

1-Tages-Spanne:

$79.92

$81.16

1-Wochen-Bereich:

$73.97

$81.16

52-Wochen-Spanne:

$57.00

$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Firmenname

Novo Nordisk Adr

Sektor

Healthcare (1170)

Branche

Drug Manufacturers - General (19)

Telefon

Adresse

Mitarbeiter

77,406

Twitter

@novonordisk

Nächster Verdiensttermin

2024-12-06

Neueste SEC-Einreichungen

NVO's Discussions on Twitter

Vergleichen Sie NVO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NVO Novo Nordisk Adr	81.05	322.81B	43.59B	15.04B	10.74B	3.3766
LLY Lilly Eli Co	812.03	687.38B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	156.66	369.72B	89.33B	21.81B	18.57B	8.99
ABBV Abbvie Inc	192.42	331.15B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	120.77	232.65B	53.22B	12.86B	14.85B	6.39

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2025-03-13	Hochstufung	Kepler	Hold → Buy
2025-03-03	Herabstufung	Stifel	Buy → Hold
2025-02-12	Eingeleitet	Morgan Stanley	Equal-Weight
2025-01-06	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-05-30	Eingeleitet	Goldman	Buy
2024-04-12	Eingeleitet	BMO Capital Markets	Outperform
2024-01-23	Eingeleitet	Morgan Stanley	Overweight
2024-01-16	Fortgesetzt	UBS	Neutral
2023-12-01	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-02	Eingeleitet	Argus	Buy
2023-07-14	Eingeleitet	HSBC Securities	Buy
2022-07-15	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-06-28	Herabstufung	UBS	Neutral → Sell
2022-06-27	Hochstufung	Exane BNP Paribas	Underperform → Neutral
2022-06-07	Hochstufung	JP Morgan	Neutral → Overweight
2022-05-31	Hochstufung	Guggenheim	Neutral → Buy
2022-04-25	Hochstufung	Cowen	Market Perform → Outperform
2022-04-12	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-03-16	Hochstufung	Deutsche Bank	Hold → Buy
2022-01-25	Herabstufung	Liberum	Hold → Sell
2021-12-20	Herabstufung	JP Morgan	Overweight → Neutral
2021-12-17	Herabstufung	Deutsche Bank	Buy → Hold
2021-01-20	Herabstufung	Credit Suisse	Outperform → Neutral
2021-01-15	Eingeleitet	Deutsche Bank	Buy
2020-09-29	Eingeleitet	Berenberg	Hold
2020-07-06	Herabstufung	BofA Securities	Buy → Neutral
2020-05-11	Herabstufung	UBS	Buy → Neutral
2020-05-04	Eingeleitet	Cowen	Market Perform
2020-03-16	Hochstufung	BofA/Merrill	Neutral → Buy
2020-01-03	Herabstufung	Guggenheim	Buy → Neutral
2019-11-18	Hochstufung	Barclays	Equal Weight → Overweight
2019-09-17	Hochstufung	Citigroup	Neutral → Buy
2019-08-30	Herabstufung	Jefferies	Hold → Underperform
2019-06-20	Herabstufung	Deutsche Bank	Buy → Hold
2019-06-11	Hochstufung	Barclays	Underweight → Equal Weight
2019-04-29	Hochstufung	Credit Suisse	Neutral → Outperform
2019-01-29	Eingeleitet	Exane BNP Paribas	Outperform
2018-12-11	Fortgesetzt	Jefferies	Hold
2018-10-09	Eingeleitet	Guggenheim	Buy
2017-12-29	Hochstufung	JP Morgan	Underweight → Neutral
2017-12-06	Hochstufung	BofA/Merrill	Neutral → Buy
2017-12-01	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2017-09-25	Herabstufung	Exane BNP Paribas	Outperform → Neutral
2017-09-06	Hochstufung	BofA/Merrill	Underperform → Neutral

Alle ansehen

Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten

Jun 12, 2025

Why Novo Nordisk Stock Pumped Higher on Thursday - The Motley Fool

Jun 12, 2025

May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025

May 30, 2025

European ADRs Show Resilience In US Market - Finimize

May 30, 2025

May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025

May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025

May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025

May 10, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 10, 2025

May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025

May 08, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria

May 08, 2025

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

Novo Nordisk cuts guidance but says generic competition will ease - Sharecast.com

May 07, 2025

May 06, 2025